推荐产品
生物源
mouse
共軛
unconjugated
抗體表格
purified immunoglobulin
抗體產品種類
primary antibodies
無性繁殖
HER2-96, monoclonal
形狀
buffered aqueous solution
分子量
antigen 185 kDa (complete protein)
antigen 97-115 kDa (extracellular ligand-binding domain)
物種活性
human
濃度
~2 mg/mL
技術
immunoprecipitation (IP): 0.5-1 μg/test using RIPA lysate of cultured CB2 cells (CHO cell line transfected with erbB-2)
indirect ELISA: suitable
microarray: suitable
同型
IgG1
UniProt登錄號
運輸包裝
dry ice
儲存溫度
−20°C
目標翻譯後修改
unmodified
基因資訊
human ... ERBB2(2064)
一般說明
Monoclonal Anti-c-erbB-2 (HER-2, Neu) (mouse IgG1 isotype) is derived from the (human epidermal growth factor receptor 2) HER2-96 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from a BALB/c mouse immunized with a purified extracellular domain of human erbB-2, from transfected cells. The human erbB-2 oncogen (also known as HER2, HER-2 or neu) encodes a transmembrane growth factor orphan receptor with a M.W. of 185 kDa (p185). The complete protein consists of an internal cytoplasmic structure with tyrosine kinase activity, a short hydrophobic transmembrane section and an extracellular ligand-binding domain (ECD).
免疫原
purified extracellular domain of human erbB-2 from transfected cells.
應用
Monoclonal Anti-c-erbB-2 antibody produced in mouse has been used in :
- enzyme linked immunosorbent assay (ELISA)
- immunoprecipitation
- immunohistochemistry
- studies on receptor internalization, phosphorylation, ligand binding and tumor growth inhibition
生化/生理作用
Erb-b2 receptor tyrosine kinase 2 (ErbB-2) has a pivotal role in signal transduction, where it can stimulate the signal even in the absence of ligand by forming heterodimers with erbB-1/EGF-R, erbB-3, and erbB-4 and hence can modifies ligand affinity. Thus, erbB-2 alters the intracellular responses elicited by EGF and NDF. This control is due to the fact that erbB-2, when in complex with another erbB family receptor, decelerates the rate of ligand dissociation. Therefore, erbB-2 may act as a signalling subunit for other receptors rather than a true growth factor receptor. Because overexpression of the erbB-2 proto-oncogene is frequently associated with an aggressive clinical course of certain human adenocarcinomas, the encoded protein is an attractive target for immunotherapy. Indeed, antibodies to erbB-2 were found to block the crosstalk with growth factor receptors. In addition, receptor overexpression is considered a predictor of poor survival and short time of relapse.
外觀
0.01M 磷酸缓冲盐溶液,pH 7.4,含 15mM 叠氮化钠。
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our 产品选型工具.
儲存類別代碼
10 - Combustible liquids
水污染物質分類(WGK)
WGK 2
閃點(°F)
Not applicable
閃點(°C)
Not applicable
International journal of molecular sciences, 18(2) (2017-02-18)
In cancer, vulnerable breast epithelium malignance tendency correlates with number and activation of ErbB receptor tyrosine kinases. In the presented work, we observe ErbB receptors activated by irradiation-induced DNA injury or neuregulin- 1 β application, or alternatively, attenuated by a
Proceedings of the National Academy of Sciences of the United States of America, 96(9), 4995-5000 (1999-04-29)
The erbB-2/HER2 oncogene is overexpressed in a significant fraction of human carcinomas of the breast, ovary, and lung in a manner that correlates with poor prognosis. Although the encoded protein resembles several receptors for growth factors, no high affinity ligand
Oncogene, 14(17), 2099-2109 (1997-05-01)
ErbB-2 is an orphan receptor that belongs to a family of tyrosine kinase receptors for either epidermal growth factor (EGF) or Neu differentiation factor (NDF/neuregulin). Because overexpression of the erbB-2 proto-oncogene is frequently associated with an aggressive clinical course of
HER2-Associated Radioresistance of Breast Cancer Stem Cells Isolated from HER2-Negative Breast Cancer Cells
Clinical Cancer Research, 18(24), 6634-6647 (2012)
Clinical cancer research : an official journal of the American Association for Cancer Research, 18(24), 6634-6647 (2012-10-24)
To understand the role of HER2-associated signaling network in breast cancer stem cells (BCSC) using radioresistant breast cancer cells and clinical recurrent breast cancers to evaluate HER2-targeted therapy as a tumor eliminating strategy for recurrent HER2(-/low) breast cancers. HER2-expressing BCSCs
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门